HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COM
Total 13F shares
2,057,772
Share change
+164,181
Total reported value
$4,174,105
Price per share
$2.03
Number of holders
17
Value change
+$476,661
Number of buys
8
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q4 2017

As of 31 Dec 2017, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,057,772 shares. The largest 10 holders included FMR LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Private Wealth Partners, LLC, Vanguard Group Inc, PUTNAM INVESTMENTS LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, OxFORD Asset Management LLP, GEODE CAPITAL MANAGEMENT, LLC, COMMONWEALTH EQUITY SERVICES, LLC., and MORGAN STANLEY. This page lists 17 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.